MVision AI
News and Articles

Keep up to date with our latest articles

Hot Topics 🔥

Press Room

23.3.2023

Press Release: MVision AI raises 5.4M€ to make same-day cancer treatment the new standard

HELSINKI, Finland - March 23, 2023 MVision AI raises 5.4M€ to make same-day cancer treatment the new standard MVision AI is the first cloud-based AI-powered radiotherapy planning solution for treating cancer. MVision uses artificial intelligence to automate cancer treatments with its unique automatic segmentation tool. The next-generation technology speeds up…

Press Releases

20.2.2023

Perspectives on the implementation of AI-based solutions for Radiation Oncology – Where are we?

One of the main characteristics of humans, compared to most other living creatures, is the ability of making tools. Progress has been linked to discoveries and the development of new devices. People have always tried to enhance their capabilities, and our days are not different. But how do we perceive…

Articles

20.1.2023

MVision AI: your data is protected!

MVision AI not only provides unique AI-powered solutions for Radiotherapy treatment planning but also follows the highest standards of data protection for clinics and their patients. This is of utmost importance to us so we are very excited to celebrate Data Privacy Week and explain how we protect your data…

Articles

16.1.2023

Deep learning to generate synthetic CT Images from MR for Radiotherapy treatment planning

The generation of synthetic images has greatly advanced in recent years due to the progress of artificial intelligence. Some of the applications have recently been widely popularized in media, especially art and fashion generation and videos/photos creation of realistic-looking human faces¹. The image-to-image translation is a special case of synthetic…

Articles

9.1.2023

NCCC Evaluation of MVision AI contouring software

S Warren, N Richmond MVision AI software has been under evaluation at NCCC (Newcastle upon Tyne Hospitals NHS Foundation Trust) since 28 February 2022* in order to: 1. compare AI contour quality and consistency with manual contouring; 2. estimate potential improvements in efficiency; 3. identify opportunities to improve clinical workflow.…

Articles

3.1.2023

MVision: 2022 year in review

2022 came to an end. Seeing our names of customers, the number of scans and countries marked on the map, we know, we reached our accomplishments for 2022, because of uniqueness of our solution, the trust of our customers and the commitment of our team. Stepping into the year 2023,…

Articles, News

14.12.2022

Distribution partnership agreement between MVision AI and Tecnosan

Finland, Helsinki, December 14, 2022 – MVision AI, the leading provider of AI-powered Guideline Based Segmentation solution for Radiotherapy planning and Tecnosan, advanced healthcare technology for radiotherapy and medical physics supplier in Italy announced cooperation and signing of a new Distribution partnership agreement. Both companies will closely cooperate on current…

Press Releases

11.8.2022

Cancer in Ireland – Raising Survival Rates

Every year, almost 45.000 people in Ireland are diagnosed with cancer, making Ireland the country with the highest cancer incidence in Europe. The 5 most diagnosed types of cancer in Ireland are: Skin cancer Prostate cancer Breast cancer Bowel cancer Lung cancer 1 out of 4 deaths in Ireland can…

Articles

3.8.2022

MVision’s GBS™ is Featured in 5 Posters at the German Society of Radiation Oncology (DEGRO) Annual Meeting

This week, we're focusing on high-impact research presented during the German Society of Radiation Oncology (DEGRO) Annual Meeting. Five posters included a focus on MVision’s guideline-based segmentation, GBS™, solution (also available as an on-premise solution).   Development of an AI-based auto-contouring of upper and lower jaw segments for optimized radiation planning…

News

29.7.2022

Improving Tools to Fight Glioblastoma

 Background Glioblastoma multiforme represents approximately half of the cases of central nervous system malignant tumors. The median age at diagnosis is 64 years, and the incidence was reported to be approximately 3 cases in 100 000 people. Genetic conditions, such as Li Fraumeni and Lynch Syndrome,  are associated with a…

Articles

17.6.2022

RT for Prostate Cancer: Faster and Better – Is it Possible?

Background Worldwide, more than 1 400 000 men were diagnosed with prostate cancer in 2020, and it is estimated that one third will need radiotherapy during their treatment. (more…)

Articles

31.5.2022

MVision AI Receives FDA 510(k) Clearance for Guideline-Based Segmentation Radiotherapy Software

Helsinki, 31st of May, 2022 - MVision AI announces that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for guideline-based, AI-powered software for automatic segmentation for radiotherapy. (more…)

News, Press Releases

Testimonials

Hear what people say about us.

Customer Portfolio